Understanding how Tet1 affects intestinal stem cells
Determining the role of Tet1 in facultative intestinal stem cells
['FUNDING_FELLOWSHIP'] · EMORY UNIVERSITY · NIH-11057710
This study is looking at how a protein called Tet1 helps the stem cells in your intestines heal after they get hurt, especially from treatments like chemotherapy, to find better ways to support recovery for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11057710 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Tet1, a protein involved in gene regulation, in the behavior of intestinal stem cells that help maintain the health of the intestinal lining. It focuses on how these stem cells can regenerate after injury, which is often caused by cancer treatments like chemotherapy. By examining the genetic mechanisms behind this regeneration, the research aims to uncover how to better support the healing process in patients who have experienced damage to their intestinal cells. The study employs advanced techniques to analyze gene expression and cellular changes in response to injury.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults who have undergone chemotherapy or radiation therapy and are experiencing intestinal damage.
Not a fit: Patients who have not received cancer treatment or do not have intestinal health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that enhance the recovery of intestinal health in cancer patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of genetic factors in stem cell regeneration, suggesting that this approach could yield valuable insights.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JANTO, NICOLAS VAUGHAN — EMORY UNIVERSITY
- Study coordinator: JANTO, NICOLAS VAUGHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy